Provided by Tiger Trade Technology Pte. Ltd.

Bristol-Myers Squibb

59.70
+0.11000.18%
Post-market: 59.24-0.4605-0.77%16:28 EDT
Volume:11.04M
Turnover:658.84M
Market Cap:121.53B
PE:13.14
High:60.10
Open:59.45
Low:59.01
Close:59.59
52wk High:68.64
52wk Low:42.52
Shares:2.04B
Float Shares:2.03B
Volume Ratio:0.84
T/O Rate:0.54%
Dividend:2.51
Dividend Rate:4.20%
EPS(TTM):4.54
EPS(LYR):3.46
ROE:46.60%
ROA:10.72%
PB:5.45
PE(LYR):17.25

Loading ...

Bristol-Myers Squibb is Maintained at Underweight by Morgan Stanley

Dow Jones
·
Yesterday

Morgan Stanley Adjusts Price Target on Bristol-Myers Squibb to $41 From $40

MT Newswires Live
·
Yesterday

Vir Names David Liu Chief Medical Officer Effective Oct. 12, 2026

Reuters
·
Yesterday

Why Vaxcyte Chose A 1.5% Convertible

Macro World​
·
Yesterday

Bristol Myers Squibb (BMY) Expands CAMZYOS Approval, Is The Stock Still A Bargain?

Simply Wall St.
·
Yesterday

Bristol Myers Squibb Co. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Yesterday

From Lilly Deal to Market Darling: Inside Ginkgo's 120% Monthly Run

Bellwether Stocks Movement
·
Oct 06

Bristol Myers Squibb Co. Stock Sheds 3.8%, Underperforms Peers

Dow Jones
·
Oct 06

Bristol-Myers Squibb Co: Prelim Total Acquired Iprd and Licensing Income $1,536 Mln for Three Months Ended September 30, 2026

THOMSON REUTERS
·
Oct 06

Bristol-Myers Squibb Shares Fall After Leerink Partners Downgrade

MT Newswires Live
·
Oct 06

S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT

Reuters
·
Oct 06

Bristol-Myers Squibb Co Stock (BMY) Moved Down by 3.56% on Oct 5: What Investors Need To Know

TradingKey
·
Oct 05

Movement Alert|Bristol-Myers Squibb Intraday Decline 3.03%, Leerink Partners Downgrades Rating and Price Target

Market Focus
·
Oct 05

Leerink Downgrades Bristol Myers, Flags Pipeline Risks

Reuters
·
Oct 05

Immunome Issues 4,425,487 Shares to Bristol-Myers Squibb in Unregistered Sale

Reuters
·
Oct 05

Leerink Partners Downgrades Bristol-Myers Squibb to Market Perform From Outperform, Cuts Price Target to $59 From $73

MT Newswires Live
·
Oct 05

Bristol-Myers Squibb Company : Leerink Partners Cuts to Market Perform from Outperform; Cuts Target Price to $59 from $73

THOMSON REUTERS
·
Oct 05

One Molecule, Three Diseases, $1.55 Billion — Inside CSL's Bet

Bellwether Stocks Movement
·
Oct 05

Merck Doubled Off Its Lows — And Analysts Still See More Room

Bellwether Stocks Movement
·
Oct 05

CSL Bets $1.6 Billion on a Drug That Hasn't Finished Phase 2

Bellwether Stocks Movement
·
Oct 05